Immuneering (NASDAQ:IMRX)highlights three key preclinical datasets indicating the potential of its lead product candidate IMM-1-104.
IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts the kinase suppressor of RAS 1 and 2 ((KSR1/2)) for the treatment of advanced solid tumors in patients harboring RAS mutant tumors.
Preclinical data showed broad antitumor activity across KRAS, NRAS and BRAF mutant tumor models, established novel mechanism of action for its dual MEK inhibition and showed synergies with Sotorasib in KRAS-G12C mutant pancreatic cancer.
The company anticipates submission of an Investigational New Drug application (IND) for IMM-1-104 to the U.S. FDA in the first quarter of 2022.